FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model

Authorized Users Only
2012
Authors
Stepanović-Petrović, Radica
Micov, Ana
Tomić, Maja
Ugrešić, Nenad
Article (Published version)
Metadata
Show full item record
Abstract
BACKGROUND: We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/antiedematous effects in the same model of localized inflammation and whether opioidergic, adrenergic, purinergic, 5-HTergic, and GABAergic receptors are involved in its antihyperalgesic action. METHODS: Rats were intraplantarly (IPL) injected with carrageenan. A paw pressure test was used to determine the effect/s of (a) levetiracetam when applied IPL, on carrageenan-induced hyperalgesia, and (b) naloxone (a nonselective opioid receptor antagonist), CTAP (a selective mu-opioid receptor antagonist); yohimbine (a selective alpha(2)-adrenoceptor antagonist), BRL 44408 (a selective alpha(2A)-adrenoceptor antagonist), MK-912 (a selective alpha(2C)-adrenoceptor antagonist); caffeine (a nonselective adenosine receptor antagonist), DPCPX (a selective adenosine... A(1) receptor antagonist); methysergide (a nonselective 5-HT receptor antagonist), GR 127935 (a selective 5-HT1B/1D receptor antagonist); and bicuculline (a selective GABA(A) receptor antagonist), all applied IPL, on the levetiracetam-induced antihyperalgesia. Moreover, levetiracetam's influence on paw inflammatory edema was measured by plethysmometry. RESULTS: Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan. Naloxone (75-300 nmol/paw), CTAP (1-5 nmol/paw); yohimbine (130-520 nmol/paw), BRL 44408 (50-200 nmol/paw), MK-912 (5-20 nmol/paw); caffeine (500-1500 nmol/paw), DPCPX (3-30 nmol/paw); methysergide (10-100 nmol/paw) and GR 127935 (50-200 nmol/paw); but not bicuculline (400 nmol/paw), significantly depressed the antihyperalgesic effects of levetiracetam (1000 nmol/paw). The effects of levetiracetam and antagonists were attributed to local peripheral effects because they were not observed after administration into the contralateral hindpaw. CONCLUSIONS: Our results show that levetiracetam produces local peripheral antihyperalgesic and antiedematous effects in a rat model of localized inflammation. Antihyperalgesia is at least in part mediated by peripheral mu-opioid, alpha(2A,C)-adrenergic, A(1) adenosine, and 5-HT1B/1D receptors, but not by GABA(A) receptors. These findings could contribute toward a better understanding of the analgesic effects of levetiracetam, and improved treatments of inflammatory pain with a lower incidence of systemic side effects and drug interactions of levetiracetam. (Anesth Analg, 2012;115:1457-66)

Source:
Anesthesia and Analgesia, 2012, 115, 6, 1457-1466
Publisher:
  • Lippincott Williams & Wilkins, Philadelphia
Funding / projects:
  • Examination of mechanisms of action, toxicity and interactions of adjuvant analgesics (RS-175045)

DOI: 10.1213/ANE.0b013e31826c7fc2

ISSN: 0003-2999

PubMed: 23144430

WoS: 000311593800031

Scopus: 2-s2.0-84870243260
[ Google Scholar ]
36
31
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/1679
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Micov, Ana
AU  - Tomić, Maja
AU  - Ugrešić, Nenad
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1679
AB  - BACKGROUND: We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/antiedematous effects in the same model of localized inflammation and whether opioidergic, adrenergic, purinergic, 5-HTergic, and GABAergic receptors are involved in its antihyperalgesic action. METHODS: Rats were intraplantarly (IPL) injected with carrageenan. A paw pressure test was used to determine the effect/s of (a) levetiracetam when applied IPL, on carrageenan-induced hyperalgesia, and (b) naloxone (a nonselective opioid receptor antagonist), CTAP (a selective mu-opioid receptor antagonist); yohimbine (a selective alpha(2)-adrenoceptor antagonist), BRL 44408 (a selective alpha(2A)-adrenoceptor antagonist), MK-912 (a selective alpha(2C)-adrenoceptor antagonist); caffeine (a nonselective adenosine receptor antagonist), DPCPX (a selective adenosine A(1) receptor antagonist); methysergide (a nonselective 5-HT receptor antagonist), GR 127935 (a selective 5-HT1B/1D receptor antagonist); and bicuculline (a selective GABA(A) receptor antagonist), all applied IPL, on the levetiracetam-induced antihyperalgesia. Moreover, levetiracetam's influence on paw inflammatory edema was measured by plethysmometry. RESULTS: Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan. Naloxone (75-300 nmol/paw), CTAP (1-5 nmol/paw); yohimbine (130-520 nmol/paw), BRL 44408 (50-200 nmol/paw), MK-912 (5-20 nmol/paw); caffeine (500-1500 nmol/paw), DPCPX (3-30 nmol/paw); methysergide (10-100 nmol/paw) and GR 127935 (50-200 nmol/paw); but not bicuculline (400 nmol/paw), significantly depressed the antihyperalgesic effects of levetiracetam (1000 nmol/paw). The effects of levetiracetam and antagonists were attributed to local peripheral effects because they were not observed after administration into the contralateral hindpaw. CONCLUSIONS: Our results show that levetiracetam produces local peripheral antihyperalgesic and antiedematous effects in a rat model of localized inflammation. Antihyperalgesia is at least in part mediated by peripheral mu-opioid, alpha(2A,C)-adrenergic, A(1) adenosine, and 5-HT1B/1D receptors, but not by GABA(A) receptors. These findings could contribute toward a better understanding of the analgesic effects of levetiracetam, and improved treatments of inflammatory pain with a lower incidence of systemic side effects and drug interactions of levetiracetam. (Anesth Analg, 2012;115:1457-66)
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Anesthesia and Analgesia
T1  - The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model
VL  - 115
IS  - 6
SP  - 1457
EP  - 1466
DO  - 10.1213/ANE.0b013e31826c7fc2
ER  - 
@article{
author = "Stepanović-Petrović, Radica and Micov, Ana and Tomić, Maja and Ugrešić, Nenad",
year = "2012",
abstract = "BACKGROUND: We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/antiedematous effects in the same model of localized inflammation and whether opioidergic, adrenergic, purinergic, 5-HTergic, and GABAergic receptors are involved in its antihyperalgesic action. METHODS: Rats were intraplantarly (IPL) injected with carrageenan. A paw pressure test was used to determine the effect/s of (a) levetiracetam when applied IPL, on carrageenan-induced hyperalgesia, and (b) naloxone (a nonselective opioid receptor antagonist), CTAP (a selective mu-opioid receptor antagonist); yohimbine (a selective alpha(2)-adrenoceptor antagonist), BRL 44408 (a selective alpha(2A)-adrenoceptor antagonist), MK-912 (a selective alpha(2C)-adrenoceptor antagonist); caffeine (a nonselective adenosine receptor antagonist), DPCPX (a selective adenosine A(1) receptor antagonist); methysergide (a nonselective 5-HT receptor antagonist), GR 127935 (a selective 5-HT1B/1D receptor antagonist); and bicuculline (a selective GABA(A) receptor antagonist), all applied IPL, on the levetiracetam-induced antihyperalgesia. Moreover, levetiracetam's influence on paw inflammatory edema was measured by plethysmometry. RESULTS: Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan. Naloxone (75-300 nmol/paw), CTAP (1-5 nmol/paw); yohimbine (130-520 nmol/paw), BRL 44408 (50-200 nmol/paw), MK-912 (5-20 nmol/paw); caffeine (500-1500 nmol/paw), DPCPX (3-30 nmol/paw); methysergide (10-100 nmol/paw) and GR 127935 (50-200 nmol/paw); but not bicuculline (400 nmol/paw), significantly depressed the antihyperalgesic effects of levetiracetam (1000 nmol/paw). The effects of levetiracetam and antagonists were attributed to local peripheral effects because they were not observed after administration into the contralateral hindpaw. CONCLUSIONS: Our results show that levetiracetam produces local peripheral antihyperalgesic and antiedematous effects in a rat model of localized inflammation. Antihyperalgesia is at least in part mediated by peripheral mu-opioid, alpha(2A,C)-adrenergic, A(1) adenosine, and 5-HT1B/1D receptors, but not by GABA(A) receptors. These findings could contribute toward a better understanding of the analgesic effects of levetiracetam, and improved treatments of inflammatory pain with a lower incidence of systemic side effects and drug interactions of levetiracetam. (Anesth Analg, 2012;115:1457-66)",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Anesthesia and Analgesia",
title = "The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model",
volume = "115",
number = "6",
pages = "1457-1466",
doi = "10.1213/ANE.0b013e31826c7fc2"
}
Stepanović-Petrović, R., Micov, A., Tomić, M.,& Ugrešić, N.. (2012). The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model. in Anesthesia and Analgesia
Lippincott Williams & Wilkins, Philadelphia., 115(6), 1457-1466.
https://doi.org/10.1213/ANE.0b013e31826c7fc2
Stepanović-Petrović R, Micov A, Tomić M, Ugrešić N. The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model. in Anesthesia and Analgesia. 2012;115(6):1457-1466.
doi:10.1213/ANE.0b013e31826c7fc2 .
Stepanović-Petrović, Radica, Micov, Ana, Tomić, Maja, Ugrešić, Nenad, "The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model" in Anesthesia and Analgesia, 115, no. 6 (2012):1457-1466,
https://doi.org/10.1213/ANE.0b013e31826c7fc2 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB